US Stock Alert: Arcadia plunges on September 25 as main milestone not achieved and target price lowered

Arcadia September 25th: Analysis of Sharp Decline

Keywords: Primary endpoint not met, target price lowered

1. On September 24, 2026, the 60mg dose of Remefanserin in the Phase II trial for Alzheimer's disease psychosis did not reach statistical significance for the primary endpoint, and the 30mg dose showed limited improvement. The company plans to cancel the 30mg dose in subsequent Phase III trials, creating uncertainty for project efficacy and development success.

2. On September 25, 2026, multiple institutions lowered their ACAD target prices after evaluating the RADIANT results. Some institutions also reduced the probability of success for Remefanserin and postponed the expected launch date, thus lowering valuation expectations.

(Disclaimer: This content is a summary generated by AI technology using publicly available information and is for reference only. It does not constitute investment advice.)